The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | ERIC recommendations on TP53 mutation classification
Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, Italy, discusses the significance TP53 mutation status on chronic lymphocytic leukemia (CLL), as evaluated by a multicenter ERIC study comparing methods used for identifying the presence of TP53 mutations in CLL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
